Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Tumor
70%
Dutch
51%
Pediatric
48%
Pediatric Patients
40%
Acute Lymphoblastic Leukemia
37%
Overall Survival
35%
Neuroblastoma
31%
Pediatric Oncology
30%
Pediatric Leukemia
30%
High Risk
28%
Children with Cancer
28%
Wilms Tumor
27%
Event-free Survival
26%
Netherlands
25%
Acute Myeloid Leukemia
25%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
24%
Older Adults
23%
Chemotherapy
22%
Childhood Cancer
22%
95% Confidence Interval
21%
Central Nervous System Tumors
20%
Health-related Quality of Life
20%
Hematopoietic Stem Cell Transplantation
20%
Risk Factors
20%
Pediatric Cancer Patients
19%
Radiotherapy
17%
Survivors
17%
Working Diagnosis
16%
Childhood Acute Lymphoblastic Leukemia
16%
Minimal Residual Disease
15%
Pediatric Acute Lymphoblastic Leukemia
15%
Tumor Subtype
15%
Clinical Trials
15%
Cancer Treatment
15%
Hazard Ratio
14%
Targeted Therapy
14%
Melanoma
13%
Hematopoietic Cell Transplantation
13%
DNA Methylation Profiling
13%
T Cells
13%
Glioblastoma
12%
High-risk Neuroblastoma
12%
Clinical Outcomes
12%
Renal Tumor
12%
Diffuse Intrinsic Pontine Glioma
12%
Glioma
12%
Meta-analysis
12%
BCP-ALL
12%
Oncology
12%
Pheochromocytoma
11%
Randomized Controlled Trial
11%
Paraganglioma
11%
Relapsed/refractory
11%
Prognostic Value
11%
Risk Stratification
11%
Prognostic Factors
11%
RNA Sequencing (RNA-seq)
11%
Survival Rate
10%
Pediatric Cancer
10%
Phase I Study
10%
Stage III Melanoma
10%
Pembrolizumab
10%
Isocitrate Dehydrogenase 1 (IDH1)
10%
Tumor Studies
10%
Leukemia
9%
Osteosarcoma
9%
Pediatric Tumors
9%
Clinical Practice Guidelines
9%
Diffuse Glioma
9%
Phase II Trial
9%
Childhood Cancer Survivor Study
9%
Cancer Types
9%
Leukemia Patients
9%
Placebo
9%
EORTC
9%
Pediatric Glioma
9%
Pharmacokinetics
9%
Newly Diagnosed
9%
Patient Outcomes
9%
Europe
8%
Immunohistochemistry
8%
Metachromatic Leukodystrophy
8%
During Treatment
8%
Medulloblastoma
8%
Adult Patients
8%
European Organizations
8%
Improved Outcomes
8%
Clinical Practice
8%
COVID-19
8%
Odds Ratio
7%
Germline
7%
Progression-free Survival
7%
Adjuvant Therapy
7%
In Cancer
7%
Graft-versus-host Disease (GvHD)
7%
Pediatric Brain Tumor
7%
Cumulative Incidence
7%
Chronic Graft-versus-host Disease (cGVHD)
7%
Molecular Analysis
7%
Pediatric Renal Tumors
7%
Medicine and Dentistry
Pediatrics
100%
Childhood Cancer
80%
Tumor
57%
Malignant Neoplasm
57%
Neoplasm
53%
Ganglioglioma
40%
Overall Survival
37%
Acute Lymphoblastic Leukemia
36%
Diseases
34%
Adolescence
34%
Chemotherapy
34%
Ganglioneuroblastoma
28%
Pediatrics Patient
25%
Wilms' Tumor
25%
Acute Myeloid Leukemia
25%
Melanoma
24%
Event Free Survival
22%
Kidney Tumour
19%
Radiation Therapy
19%
Central Nervous System Tumor
18%
Genetics
18%
Systematic Review
17%
Clinical Trial
17%
Oncology
17%
Hematopoietic Stem Cell Transplantation
16%
Pediatric Acute Myeloid Leukemia
16%
Pediatric Cancer
15%
Quality of Life
15%
Biological Marker
15%
Recurrent Disease
15%
Osteosarcoma
14%
Cancer
13%
Hazard Ratio
13%
Targeted Therapy
12%
Soft Tissue Sarcoma
12%
Minimal Residual Disease
12%
Magnetic Resonance Imaging
12%
Immunotherapy
12%
Cohort Analysis
12%
Prevalence
12%
Pheochromocytoma
11%
Paraganglioma
10%
Survival Rate
10%
Prognostic Factor
10%
Risk Stratification
10%
Cancer Treatment
9%
Glioblastoma
9%
Hematopoietic Cell
9%
Leukemia
8%
Adverse Event
8%
Immunohistochemistry
8%
Cumulative Incidence
8%
High Risk Population
8%
Retrospective Study
8%
Germ Cell
8%
Central Nervous System
8%
Cancer Therapy
8%
Pontine Glioma
8%
Histology
7%
DNA Methylation
7%
Meta-Analysis
7%
Metastatic Carcinoma
7%
Neuro-Oncology
7%
Adjuvant Therapy
7%
Progression Free Survival
7%
Adrenal Cortex Carcinoma
7%
Methylation
7%
Randomized Controlled Trial
7%
Treatment Outcome
7%
Metachromatic Leukodystrophy
7%
Vincristine
7%
T Cell
6%
Rhabdomyosarcoma
6%
B Cell
6%
Median Follow Up
6%
RNA Sequence
6%
Pembrolizumab
6%
Dexamethasone
6%
Infection
6%
Body Mass Index
6%
Histopathology
6%
Solid Malignant Neoplasm
6%
Odds Ratio
6%
Prospective Study
6%
Supportive Care
6%
Medulloblastoma
5%
Down Syndrome
5%
Placebo
5%
Patient Referral
5%
Intracranial Tumor
5%
Health Care Cost
5%
COVID-19
5%
Late Effect
5%
Low and Middle Income Countries
5%
Proportional Hazards Model
5%
Distant Metastasis
5%
Clear Cell Renal Cell Carcinoma
5%
Next Generation Sequencing
5%
Cross Sectional Study
5%
Fertility Preservation
5%